To what degree would costs be inflated per patient?  I'm just wondering how much price per patient would increase the total cost of a 100 patient covid trial. 

If in fact RVX were to be getting priced out of trial space for a covid trial perhaps Don should start acting like a businessman and find a BP partner who is not making billions from a vaccine.  His excuse for not finding much interest in the boardroom for a therapeutic when they making billions on vaccines only holds true for a small minority of BP. I'm sure their BP counterparts not making money on covid would seriously look at a chance to participate financially in the covid space, especially if they are also in the cardiovascular/renal space.  Don's comments would be expected from someone who understands very little about competitive business.